226 related articles for article (PubMed ID: 36192413)
1. Longitudinal evaluation of dehydroepiandrosterone (DHEA), its sulfated form and estradiol with cancer-related cognitive impairment in early-stage breast cancer patients receiving chemotherapy.
Toh YL; Tan CJ; Yap NY; Parajuli R; Lau AJ; Chan A
Sci Rep; 2022 Oct; 12(1):16552. PubMed ID: 36192413
[TBL] [Abstract][Full Text] [Related]
2. Prechemotherapy Levels of Plasma Dehydroepiandrosterone and Its Sulfated Form as Predictors of Cancer-Related Cognitive Impairment in Patients with Breast Cancer Receiving Chemotherapy.
Toh YL; Shariq Mujtaba J; Bansal S; Yeo A; Shwe M; Lau AJ; Chan A
Pharmacotherapy; 2019 May; 39(5):553-563. PubMed ID: 30892712
[TBL] [Abstract][Full Text] [Related]
3. Association of mitochondrial DNA content in peripheral blood with cancer-related fatigue and chemotherapy-related cognitive impairment in early-stage breast cancer patients: a prospective cohort study.
Chae JW; Chua PS; Ng T; Yeo AHL; Shwe M; Gan YX; Dorajoo S; Foo KM; Loh KW; Koo SL; Chay WY; Tan TJY; Beh SY; Lim EH; Lee GE; Dent R; Yap YS; Ng R; Ho HK; Chan A
Breast Cancer Res Treat; 2018 Apr; 168(3):713-721. PubMed ID: 29313215
[TBL] [Abstract][Full Text] [Related]
4. Associations of plasma brain-derived neurotrophic factor (BDNF) and Val66Met polymorphism (rs6265) with long-term cancer-related cognitive impairment in survivors of breast cancer.
Yap NY; Tan NYT; Tan CJ; Loh KW; Ng RCH; Ho HK; Chan A
Breast Cancer Res Treat; 2020 Oct; 183(3):683-696. PubMed ID: 32696315
[TBL] [Abstract][Full Text] [Related]
5. Six-month oral dehydroepiandrosterone supplementation in early and late postmenopause.
Stomati M; Monteleone P; Casarosa E; Quirici B; Puccetti S; Bernardi F; Genazzani AD; Rovati L; Luisi M; Genazzani AR
Gynecol Endocrinol; 2000 Oct; 14(5):342-63. PubMed ID: 11109974
[TBL] [Abstract][Full Text] [Related]
6. Cortisol, dehydroepiandrosterone (DHEA), and DHEA sulfate in the cerebrospinal fluid of man: relation to blood levels and the effects of age.
Guazzo EP; Kirkpatrick PJ; Goodyer IM; Shiers HM; Herbert J
J Clin Endocrinol Metab; 1996 Nov; 81(11):3951-60. PubMed ID: 8923843
[TBL] [Abstract][Full Text] [Related]
7. Adrenopause or decline of serum adrenal androgens with age in women living at sea level or at high altitude.
Gonzales GF; Góñez C; Villena A
J Endocrinol; 2002 Apr; 173(1):95-101. PubMed ID: 11927388
[TBL] [Abstract][Full Text] [Related]
8. Patient-Reported Cognitive Impairment Among Women With Early Breast Cancer Randomly Assigned to Endocrine Therapy Alone Versus Chemoendocrine Therapy: Results From TAILORx.
Wagner LI; Gray RJ; Sparano JA; Whelan TJ; Garcia SF; Yanez B; Tevaarwerk AJ; Carlos RC; Albain KS; Olson JA; Goetz MP; Pritchard KI; Hayes DF; Geyer CE; Dees EC; McCaskill-Stevens WJ; Minasian LM; Sledge GW; Cella D
J Clin Oncol; 2020 Jun; 38(17):1875-1886. PubMed ID: 32271671
[TBL] [Abstract][Full Text] [Related]
9. Relationship between cytokines and brain-derived neurotrophic factor (BDNF) in trajectories of cancer-related cognitive impairment.
Yap NY; Toh YL; Tan CJ; Acharya MM; Chan A
Cytokine; 2021 Aug; 144():155556. PubMed ID: 33985854
[TBL] [Abstract][Full Text] [Related]
10. Pharmacology and therapeutic effects of dehydroepiandrosterone in older subjects.
Legrain S; Girard L
Drugs Aging; 2003; 20(13):949-67. PubMed ID: 14561100
[TBL] [Abstract][Full Text] [Related]
11. Relationship of serum dehydroepiandrosterone (DHEA), DHEA sulfate, and 5-androstene-3 beta, 17 beta-diol to risk of breast cancer in postmenopausal women.
Dorgan JF; Stanczyk FZ; Longcope C; Stephenson HE; Chang L; Miller R; Franz C; Falk RT; Kahle L
Cancer Epidemiol Biomarkers Prev; 1997 Mar; 6(3):177-81. PubMed ID: 9138660
[TBL] [Abstract][Full Text] [Related]
12. Dehydroepiandrosterone and age-related cognitive decline.
Sorwell KG; Urbanski HF
Age (Dordr); 2010 Mar; 32(1):61-7. PubMed ID: 19711196
[TBL] [Abstract][Full Text] [Related]
13. Inflammation at diagnosis and cognitive impairment two years later in breast cancer patients from the Canto-Cog study.
Duivon M; Lequesne J; Di Meglio A; Pradon C; Vaz-Luis I; Martin AL; Everhard S; Broutin S; Rigal O; Bousrih C; Lévy C; Lerebours F; Lange M; Joly F
Breast Cancer Res; 2024 Jun; 26(1):93. PubMed ID: 38840166
[TBL] [Abstract][Full Text] [Related]
14. Low Serum Dehydroepiandrosterone and Dehydroepiandrosterone Sulfate Are Associated With Coronary Heart Disease in Men With Type 2 Diabetes Mellitus.
Zhang X; Xiao J; Liu T; He Q; Cui J; Tang S; Li X; Liu M
Front Endocrinol (Lausanne); 2022; 13():890029. PubMed ID: 35832423
[TBL] [Abstract][Full Text] [Related]
15. Biotransformation of oral dehydroepiandrosterone in elderly men: significant increase in circulating estrogens.
Arlt W; Haas J; Callies F; Reincke M; Hübler D; Oettel M; Ernst M; Schulte HM; Allolio B
J Clin Endocrinol Metab; 1999 Jun; 84(6):2170-6. PubMed ID: 10372727
[TBL] [Abstract][Full Text] [Related]
16. DHEAS prevents pro-metastatic and proliferative effects of 17ß-estradiol on MCF-7 breast cancer cells.
Upmanyu N; Bulldan A; Failing K; Scheiner-Bobis G
Biochim Biophys Acta Mol Cell Res; 2020 Feb; 1867(2):118600. PubMed ID: 31760088
[TBL] [Abstract][Full Text] [Related]
17. Stimulation of cell proliferation and estrogenic response by adrenal C19-delta 5-steroids in the ZR-75-1 human breast cancer cell line.
Poulin R; Labrie F
Cancer Res; 1986 Oct; 46(10):4933-7. PubMed ID: 2944574
[TBL] [Abstract][Full Text] [Related]
18. The association of plasma DHEA and DHEA sulfate with breast cancer risk in predominantly premenopausal women.
Tworoger SS; Missmer SA; Eliassen AH; Spiegelman D; Folkerd E; Dowsett M; Barbieri RL; Hankinson SE
Cancer Epidemiol Biomarkers Prev; 2006 May; 15(5):967-71. PubMed ID: 16702378
[TBL] [Abstract][Full Text] [Related]
19. Effects of estrogen replacement therapy on dehydroepiandrosterone, dehydroepiandrosterone sulfate, and cortisol responses to exercise in postmenopausal women.
Johnson LG; Kraemer RR; Haltom R; Kraemer GR; Gaines HE; Castracane VD
Fertil Steril; 1997 Nov; 68(5):836-43. PubMed ID: 9389812
[TBL] [Abstract][Full Text] [Related]
20. Relation of dehydroepiandrosterone and dehydroepiandrosterone sulfate with cardiovascular disease risk factors in women: longitudinal results from the Massachusetts Women's Health Study.
Johannes CB; Stellato RK; Feldman HA; Longcope C; McKinlay JB
J Clin Epidemiol; 1999 Feb; 52(2):95-103. PubMed ID: 10201649
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
